Altimmune, Inc. Email Format
Biotechnology ResearchMaryland, United States51-200 Employees
Altimmune, Inc. is a mid-sized biotechnology company in the late stages of clinical development focused on therapies for serious liver diseases. Its lead program is a dual-action treatment designed to stimulate glucagon and GLP-1 receptor pathways in a 1:1 balance, being developed for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company is based in Gaithersburg, Maryland, and concentrates its work on liver care and related metabolic conditions. Within the biotechnology research sector, Altimmune positions itself as a late-stage candidate developer addressing liver-related illnesses. In 2026 the company expanded its offices to New Jersey and announced a relocation of its headquarters from Gaithersburg to New Jersey, reflecting geographic growth.